Oncology diagnostics are evolving from detecting cancer to guiding decisions across the entire patient journey. Screening is shifting from population-based tests to biomarker-led approaches such as Proclarix in prostate cancer, improving accuracy and reducing unnecessary investigations.
Diagnostic precision is further enhanced by molecular tools like the Prostatype Genomic Classifier, which more accurately predicts prostate cancer outcomes than traditional methods and supports decisions such as active surveillance or focal therapy. Treatment selection is also being shaped by predictive biomarkers; for example, MAF gene testing in breast cancer helps identify patients more likely to benefit from adjuvant bisphosphonate therapy.
As diagnostics advance, integration of laboratory systems, data, and clinical delivery has become essential. Source BioScience supports this shift by combining accredited cellular pathology with molecular and genomic testing capabilities, enabling end-to-end diagnostic pathways.
T: 0115 973 9012